CytRx To Initiate Phase 2 Clinical Trial With INNO-206 In Patients With Advanced Gastric Cancer
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients...



